AST-002

AST-002 is a preclinical small molecule targeted conjugate (SMDC) being developed by Ascentawits Pharmaceuticals for the treatment of prostate cancer and small cell lung cancer (SCLC). The drug is built upon the company's proprietary platform, which involves the conjugation of a small-molecule targeting fragment to a cytotoxic or chemotherapy payload. This design is intended to selectively deliver the therapeutic agent to tumor cells, thereby enhancing efficacy while minimizing systemic toxicity. As of early 2024, AST-002 is in the preclinical registration study phase, though its specific molecular target remains undisclosed by the developer.